Noun
ustekinumab (uncountable)
(pharmacology) A human monoclonal antibody directed against interleukin 12 and interleukin 23, in clinical trials for multiple sclerosis, psoriasis, and psoriatic arthritis.
As for the results of the trial, 75.3% of patients in the ultIMMa-1 trial achieved PASI 90 response at week 16 compared to 42.0% of ustekinumab patients and 4.9% of placebo patients. Source: Internet
How should I use ustekinumab (Stelara, Stelara PFS)? Source: Internet
During his presentation Gordon noted that both studies met the primary endpoints, as well as all 15 ranked secondary endpoints, including nine that compared risankizumab to ustekinumab. Source: Internet